The CAR-T Therapy by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The CAR-T Therapy Market:
https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report
According to The Business Research Company’s CAR-T Therapy, The car-t therapy pipeline analysis market size has grown rapidly in recent years. It will grow from $2.15 billion in 2023 to $2.55 billion in 2024 at a compound annual growth rate (CAGR) of 19.1%. The growth in the historic period can be attributed to increases in healthcare expenditure, increase in pharmaceutical r&d expenditure and advances in drug discovery.
The car-t therapy pipeline analysis market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to increase in blood cancer incidence rate, rise in healthcare expenditure, strong pipeline of drugs and rising focus on car-t therapy. Major trends in the forecast period include investing in the r&d for creating remodeled car-t therapy to avoid neurological side-effects, creating off-the-shelf allogeneic car-t therapy for advanced cancer treatment, manufacturing next-generation car t cells for improved treatment of high-grade glioma, investing in ai and machine learning solutions to optimize future car-t therapy, carrying out strategic collaborations to boost innovations, collaborating or acquiring competitor companies to expand car-t therapy portfolio, and investing in the car-t therapy to make it more effective.
The CAR-T therapy market is driven by the increasing financial support provided by different organizations to promote the development and consumption of CAR-T therapy. The government and non-government organizations provide financial support to the companies in the CAR-T therapy market for research and development and the patients for their treatment of acute lymphoblastic leukemia (ALL). For instance, in December 2021, the University of California San Diego School of Medicine (CA, USA) was granted a funding of US$ 4.1 million for the development of novel chimeric antigen receptor (CAR-T) cell therapy. The grant was awarded by California Institute for Regenerative Medicine (CIRM; CA, USA) governing board. The financial support provided by different organizations towards CAR-T therapy positively drives the growth of the CAR-T therapy market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=6670&type=smp
The car-t therapy pipeline analysis market covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Target Antigen: CD19, CD22, BCMA, Other Target Antigens
3) By Application: Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Other Applications
The companies in the CAR-T therapy market are conducting clinical trials to assess the ability of CAR-T therapy to treat multiple myeloma. Multiple myeloma is a type of white blood cell cancer where the cancer cells accumulate in the bone marrow and surrounds the healthy blood cells. CAR-T therapy is being tested as a treatment for multiple myeloma. CAR-T cells are modified to target the multiple myeloma causing cells to treat the relapsed or refractory multiple myeloma (RRMM). For instance, in December 2021, Novartis announced the introduction of T-Charge™, the company’s next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. The product was in the early clinical stage (Phase I).
The car-t therapy market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
